Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Cardilin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 12, 2024
Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncologyMarcus Baaz, Tim Cardilin, Mats Jirstrand
CPT: Pharmacometrics & Systems Pharmacology|June 10, 2023
Model-based prediction of progression-free survival for combination therapies in oncologyMarcus Baaz, Tim Cardilin, Mats Jirstrand
Mathematical Biosciences|April 8, 2021
Optimization of additive chemotherapy combinations for an in vitro cell cycle model with constant drug exposuresTim Cardilin, Torbjörn Lundh, Mats Jirstrand
European Journal of Pharmacology|July 24, 2018
Evaluation and translation of combination therapies in oncology - A quantitative approachTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
Journal of Theoretical Biology|October 19, 2024
Probabilistic analysis of tumor growth inhibition models to Support trial designMarcus Baaz, Tim Cardilin, Torbjörn Lundh, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2022
Optimized scaling of translational factors in oncology: from xenografts to RECISTMarcus Baaz, Tim Cardilin, Floriane Lignet, et al.
Clinical Pharmacokinetics|October 12, 2023
Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)Sebastian Sten, Tim Cardilin, Madeleine Antonsson, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2019
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agentsTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2017
Model-Based Evaluation of Radiation and Radiosensitizing Agents in OncologyTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
BMC Cancer|May 6, 2023
Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncologyMarcus Baaz, Tim Cardilin, Floriane Lignet, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 12, 2024
Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncologyMarcus Baaz, Tim Cardilin, Mats Jirstrand
CPT: Pharmacometrics & Systems Pharmacology|June 10, 2023
Model-based prediction of progression-free survival for combination therapies in oncologyMarcus Baaz, Tim Cardilin, Mats Jirstrand
Mathematical Biosciences|April 8, 2021
Optimization of additive chemotherapy combinations for an in vitro cell cycle model with constant drug exposuresTim Cardilin, Torbjörn Lundh, Mats Jirstrand
European Journal of Pharmacology|July 24, 2018
Evaluation and translation of combination therapies in oncology - A quantitative approachTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
Journal of Theoretical Biology|October 19, 2024
Probabilistic analysis of tumor growth inhibition models to Support trial designMarcus Baaz, Tim Cardilin, Torbjörn Lundh, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2022
Optimized scaling of translational factors in oncology: from xenografts to RECISTMarcus Baaz, Tim Cardilin, Floriane Lignet, et al.
Clinical Pharmacokinetics|October 12, 2023
Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)Sebastian Sten, Tim Cardilin, Madeleine Antonsson, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2019
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agentsTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2017
Model-Based Evaluation of Radiation and Radiosensitizing Agents in OncologyTim Cardilin, Joachim Almquist, Mats Jirstrand, et al.
BMC Cancer|May 6, 2023
Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncologyMarcus Baaz, Tim Cardilin, Floriane Lignet, et al.
Pageof 2